DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

Information source: University of California, San Francisco
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Perimenopausal Bone Loss

Intervention: Fosamax (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of California, San Francisco

Official(s) and/or principal investigator(s):
Robert B. Jaffe, M.D., Principal Investigator, Affiliation: University of California, San Francisco


This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.

Clinical Details

Official title: Alendronate to Prevent Perimenopausal Transition Bone Loss

Study design: Observational Model: Case Control, Time Perspective: Prospective


Minimum age: 40 Years. Maximum age: 54 Years. Gender(s): Female.


Inclusion Criteria:

- Women ages 40-54 with symptomology of perimenopause including hot flashes, irregular

periods and vaginal dryness. Exclusion Criteria:

- Women should not be on hormone replacements, oral contraceptives, or bone mineral

enhancing medications (bisphosphonates, selective estrogen receptor modulators [SERM's], parathyroid hormone [PTH], calcitriol, fluorides)

- They should not have any abnormalities of the esophagus which delay esophageal


- They should not have hypocalcemia or severe kidney disease

- Their bone mineral density (T-score) should not be greater than 2 standard


Locations and Contacts

University of California, San Francisco, San Francisco, California 94143, United States
Additional Information

Starting date: May 2002
Last updated: May 5, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017